top pharama companies 2011 rpt

7/30/2019 Top Pharama Companies 2011 RPT

1/12

Sponsored by

www.dsm.com

PHARMACEUTICAL EXECUTIVE40

Will the recent wave of megamergers and a slow revival of biotech

financing be enough to counter a looming storm surge of patent

expirations? US health reform is the next big game-changer,

as companies seek a balance between earning profits and placating

a restive new breed of payers and the ever-expectant patient

By Jerry Cacciotti and Patrick Clinton

40 PHARMACEUTICAL EXECUTIVE


2/12

Sponsored by

www.dsm.com

MAY 2011 www.pharmexec.com 41

0%

2%

4%

6%

8%

10%

StaApotexNycomedHospiraActavisShionogiDainippon SumitomoKyowa Hakko KirinLundbeckWatsonCephalonWarner ChilcottAlconShireBiogen IdecCelgeneOtsukaUCBCSLForestAllerganGenzymeMenariniMitsubishi TanabeChugaiServierMylanBaxter InternationalGilead SciencesMerck KGaAEisaiDaiichi SankyoAstellasNovo NordiskBoehringer IngelheimTakedaBayerAmgenTevaBristol-Myers SquibbAbbottEli LillyJohnson & JohnsonAstraZenecaGlaxoSmithKlineRocheMerckSano-AventisNovartisPzer

Sta

da

Apotex

Nycom

ed

Hos

pira

Acta

vis

Shio

nogi

Dainipp

onSum

itomo

Kyow

aHakko

Kiri

n

Lundbe

ck

Watso

n

Ceph

alon

Warne

rChilc

ott

Alco

n

Shire

Biog

enIdec

Celg

ene

Ots

uka

UCBCS

L

Forest

Alle

rgan

Gen

zyme

Men

arini

Mits

ubishi

Tan

abe

Chug

ai

Servier

Mylan

Baxter

Inte

rnatio

nal

Gile

adScien

ces

Merck

KGaA

Eisai

Daiichi

Sanky

o

Astella

s

NovoNordisk

Boeh

ringe

rIng

elhe

im

Take

da

Bayer

Amge

nTe

va

Bristol-M

yers

Squibb

Abbo

tt

EliL

illy

John

son&

Joh

nson

Astr

aZen

eca

Gla

xoSm

ithKlin

e

Roch

e

Merck

San

o-Aventis

Novartis

Pzer

T

he Pharm Exec 50 ranks the

worlds largest pharmaceutical

companies by global sales of pre-scription drugsa key indicator of

market change. After last years storm

of activity, the 50 set a more placid

pace, as major players worked on inte-

grating blockbuster mergers and licked

their wounds after the latest round of

Phase III failures. Late-phase problems

are nothing new, and drug candidates

can come back from them, but there

was something particularly heartbreak-

ing about the recent crop of dead ends,

given the huge unmet medical need as-

sociated with these therapies: Pzers

Dimebon and Lillys Semagacestat for

Alzheimers, Mercks vicriviroc for HIV,

and Roches ocrelizumab for rheuma-

toid arthritis, to name just a few.

Change was most visible on the

macro level. The list of the top 10 com-

panies was shaken up a bit, with No-

vartis passing Sano-Aventis to move

into second place, and Merck jumping

from seventh to fourth. It was also therst year the top company crossed the

$50 billion mark in sales of prescrip-

tion drugsas Pzer, fueled by its ac-

quisition of Wyeth, grew from $45.4

billion in Rx sales to $58.5 billion.Meanwhile, consolidation in the ranks

continues to place a premium on size

and scale: This was the rst year that it

took $2 billion in Rx revenues to join

the 50. As recently as 10 years ago, you

could make the list with revenues of

only $500 million.

Overall, the 50 accounted for

$593.4 billion in human prescription

drug sales in 2010. That represents an

increase of nearly 8 percent from 2009,

when the total was $550.5 billion. But

among the top 10, there was slightly

better growth. This years group grew

its Rx revenues from $319.4 billion in

scal 2009 to $352.5 last yearan in-

crease of over 10 percent.

A good percentage of that growth

was fueled by mergers and acquisi-

tions. In addition to Pzer and its 29

percent increase, big gainers included

Merck (58 percent growth after its

merger with Schering Plough) and Ab-bott (up nearly 28 percent in the wake

of its acquisitions of Solvay and Pira-

mal). But the biggest single-year bump

came at a much smaller company: The

Irish rm Warner Chilcott last year ac-quired the pharmaceutical business of

Procter & Gamble, including the bil-

lion-dollar drug Actonel, and raised its

Rx revenues a whopping 111 percent to

$2.9 billion.

Looming over the yearand the

decadeis the shadow of US health-

care reform. Many in pharma feel they

have dodged the bullet of new regula-

tion and stand to gain as a projected

30 million previously uninsured Amer-

icans nally obtain insurance coveragefor healthcare. But the Patient Protec-

tion and Affordable Care Act is not the

end of the discussionits more like

the beginning of an avalanche. The

economic forces it sets in motion today

will be playing out for payers, patients,

providers, and pharma for the foresee-

able future, changing the way care is

delivered and paid for, creating numer-

ous business threats, but, with luck,

ending up with the possibility of get-ting a better alignment between help-

ing the patient and earning a prot.

Revenue Distribution o Top 50

Top 10 accounts or $352.5 billion in sales,which is 59.40% o total revenues o the Top 50

Top 20 accounts or $483.8 billion in sales,which is 81.53% o total revenues o the Top 50

*Figuresarerounded


3/12

Sponsored by

www.dsm.com


2011Rank

CompanyHQ [website]

2010 Rx Sales (USDbillions) [% change from 2009]

2010 R&D spend(USD millions)

2010 Top-Selling Drugs[USD billions]

1PfzerNew York, New York [pzer.com]

$58.5 [28.9%] $9,413Lipitor [10.7]Enbrel [3.3]

Lyrica [3.1]

2NovartisBasel, Switzerland [novartis.com]

$42.0 [9.2%] $7,100Diovan/Co-Diovan [6.1]

Gleevec/Glivec [4.3]

Lucentis [1.5]

3Sanof-AventisParis, France [sano-aventis.com]

$40.3 [4.1%] $5,147Lantus [4.7]

Lovenox [3.7]

Taxotere [2.8]

4MerckWhitehouse Station, New Jersey

[merck.com]

$39.8 [58.0%] $11,000Singulair [5.0]

Remicade [2.7]

Januvia [2.4]

5RocheBasel, Switzerland [roche.com]

$39.1 [4.1%] $8,612Avastin [6.8]

MabThera/Rituxan [6.7]

Herceptin [5.7]

6GlaxoSmithKlineBrentord, England [gsk.com]

$36.2 [4.2%] $6,126Seretide/Advair [7.9]

Pandemic Flu Vaccine [1.8]

Flixotide/Flovent [1.2]

7AstraZenecaLondon, England [astrazeneca.com]

$33.3 [1.4%] $4,200Crestor [5.7]

Nexium [5.0]

Seroquel [4.1]

8Johnson & JohnsonNew Brunswick, New Jersey [jnj.com]

$22.4 [0.4%] $4,432Remicade [4.6]

Procrit [1.9]

Risperdal [1.5]

9

Eli LillyIndianapolis, Indiana [lilly.com] $21.1 [5.4%] $4,880

Zyprexa [5.0]

Cymbalta [3.5]Alimta [2.2]

10AbbottAbbott Park, Illinois [abbott.com]

$19.9 [27.7%] $3,724Humira [6.5]

Trilipix/TriCor [1.6]

Kaletra [1.3]

Sources: corporate data (10Ks, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded

How the listings were compiled: Companies in the Pharm Exec 50 are ranked according to global human prescription drug sales. As ar as company documentation allows, generics

and vaccines are included; over-the-counter products, royalties, and contract manuacturing revenue are not. In most cases, numbers are taken rom annual reports or SEC lings or the

scal year that ended in 2010. For most American and European companies, that means the year ending Dec. 31, 2010; or many Japanese companies, it means the year ending March

31, 2010. In the case o private companies that do not report results, we have made estimates based on available data, including IMS reports. For companies that report in currencies

other than US dollars, we have converted their numbers using the midpoint average interbank rate or the last day o the scal year. Some charts that accompany this article are based on

numbers rom IMS Health. These are based on a dierent methodology and will not be consistent with the gures we have compiled rom nancial lings. Percentage growth gures should

be treated with caution, because they can be aected by fuctuating exchange rates.


4/12

Sponsored by

www.dsm.com


Latin America

Japan

Asia/Africa/Australia

Europe

North America

42.3%

29.2%

12.4%

10.8%

5.3%

25 Spiriva Handihaler

24 Copaxone

23 Atripla

22 Lovenox

21 Aricept

20 Rituxan

19 Lexapro

18 Humira

17 Zyprexa

16 Neulasta

15 Oxycontin

14 Avastin

13 Cymbalta

12 Enbrel

11 Remicade

10 Epogen

9 Actos

8 Crestor

7 Singulair

6 Seroquel

5 Abilify

4 Advair Diskus

3Plavix

2 Nexium

1 Lipitor

Source:IMS

Health,

MIDAS

Source:IMS

Health

Global Pharma Sales by RegionMarket Share Region USD in Billions Growth from 2009

Top 25 US Pharma Products by SalesProduct 2010 2009 % Change

334.8 3.2%

230.7 1.8%

98.1 13.3%

85.7 0.4%

42.0 16.3%

7.2 7.6 -5.26

6.3 6.3 FLAT

6.1 5.6 8.92 4.7 4.7 FLAT

4.6 4.0 15.00

4.4 4.2 4.76

4.1 3.7 10.81

3.8 3.0 26.66

3.5 3.4 2.94

3.3 3.2 3.13

3.3 3.2 3.13

3.3 3.3 FLAT

3.2 2.8 14.29

3.1 3.0 3.33

3.1 2.9 6.90

3.0 3.0 FLAT 3.0 2.7 11.11

2.9 2.5 16.00

2.8 2.8 FLAT

2.8 2.6 7.69

2.5 2.3 8.7

2.3 2.8 -17.86

2.2 1.9 15.79

2.2 1.7 29.41

2.0 1.7 17.65

Sales represent audited market or pharma products only (Dec. 2009Dec 2010)

IMS gures do not account or o-invoice discounts/rebates and can vary rom reported mr sales

Figures (rounded) in US billions

Worldwide Totals: $791.4 4.2%

TOTAL US SCRIP MARKET: 2010: $307.4 2009: $300.3 2.36%


5/12

Sponsored by

www.dsm.com


2011Rank

CompanyHQ [website]


2010 R&D spend(USD Millions)


11Bristol-Myers SquibbNew York [bms.com]

$19.5 [3.6%] $3,566 Plavix [6.7]

12TevaPetach Tikva, Israel [tevapharm.com]

$16.1 [16.0%] $933 Copaxone [2.9]

13

AmgenThousand Oaks, Caliornia [amgen.com] $14.7

[1.8%]

$2,894Neulasta/Neupogen [4.8]

14BayerLeverkusen, Germany [bayer.com]

$14.5 [3.6%] $2,320 Betaeron/Betaseron [1.6]

15TakedaOsaka, Japan [takeda.com]

$14.2 [0.1%] $3,198 Actos/Glustin [4.2]

16Boehringer IngelheimIngelheim, Germany

[boehringer-ingelheim.com]

$12.9 [10.8%] $3,056 Spiriva [3.8]

17Novo NordiskBagsvaerd, Norway [novonordisk.com]

$10.8 [9.9%] $1,709 NovoRapid [2.1]

18 AstellasTokyo, Japan [astellas.com] $10.5 [6.0%] $2,109 Progra[1.9]

19Daiichi SankyoTokyo, Japan [daiichisankyo.com]

$9.8 [20.0%] $2,124 Olmesartan [2.6]

20EisaiTokyo, Japan [eisai.com]

$8.4 [8.0%] $1,932 Aricept [3.5]



6/12

Sponsored by

www.dsm.com


20 Immunostimulating Agents

19 Anti-Alzheimers

18 Hormonal Contraceptives

17 Vaccines (Pure, Combo, Other)

16 Antiepileptics

15 Multiple Sclerosis

14 Erythropoietins

13 Platelet Aggregation Inhibitors

12 ADHD

11 Narcotic Analgesics

10 Angiotensin II

9 HIV Antivirals

8 Autoimmune Diseases

7 Antidepressants

6 Antiulcerants

5 Antipsychotics

4 Antidiabetes

3 Lipid Regulators

2 Respiratory Agents

1 Oncologics

20 Hypnotics & Sedatives

19 Vitamins & Minerals

18 Macrolides & Similar Type

17 Penicillins

16 Angiotensin II

15 Hormonal Contraceptives

14 Antirheumatics

13 Calcium Antagonists (Plain & Combo)

12 Thyroid Preps

11 Tranquilizers

10 Antiepileptics

9 Diuretics

8 Anti-ulcerants


6 Antidiabetes

5 Ace Inhibitors

4 Beta Blockers (Plain & Combo)


2 Antidepressants

1 Lipid Regulators

Top 20 Therapeutic Classes by SpendingProduct 2010 2009 % Change

Top 20 Therapeutic Classes by PrescriptionsClass 2010 2009 % Change

22.3 21.5 3.72

19.3 18.1 6.63

18.8 18.6 1.08

16.9 15 12.66

16.1 14.7 9.52

11.9 14.1 -15.60

11.6 11.5 0.87

10.6 9.7 9.28

9.2 8.2 12.19

8.7 8.6 1.16

8.4 8.0 5.00

7.2 6.3 14.28

7.1 6.5 9.23

6.1 6.3 -3.17

5.7 4.9 16.33

5.6 6.9 -18.84

5.0 4.6 8.69

4.8 4.7 2.13

4.5 4.0 12.5

4.2 4.1 2.44

255.4 249.7 2.28

253.6 246.1 3.05

244.3 241.0 1.37

191.5 167.8 14.12

168.7 165.7 1.81

165.0 159.0 3.77

153.3 152.4 0.59

147.1 145.7 0.96

131.0 131.7 -0.53 121.7 115.3 5.55

108.6 104.0 4.42

107.2 105.3 1.8

97.9 94.9 3.16

95.0 92.5 2.70

92.3 93.9 -1.70

83.7 84.4 -0.83

76.1 76.6 -0.65

73.9 69.3 6.64

71.9 69.8 3.01

66.0 65.5 0.76

Figures (rounded) in USD billionsTherapy Class dened using ATC-dened product groups and synthesized based on proprietary IMS Health denitons

Immunostimulating Agents excludes intererons

Rx gures (rounded) in millions;Therapy classes dened using ATC dened product groups and synthesized based on proprietary IMS Health denitions

Source:IMS

Health

Source:IMS

Health

TOTAL US SCRIP MARKET: 2010: 3,995.2 2009: 3,949.2 1.16%



7/12

Sponsored by

www.dsm.com


2011Rank

CompanyHQ [website]




21Merck KGaADarmstadt, Germany [merck.de]

$7.8 [0.4%] $1,547 Rebi[2.2]

22Gilead SciencesFoster City, Caliornia [gilead.com]

$7.4 [14.2%] $1,073 Atripla [3.0]

23Baxter International

Deerfeld, Illinois [baxter.com]

$5.6 [1.3%] $915 Advate [1.7]

24MylanCanonsburg, Pennsylvania [mylan.com]

$5.2 [7.5%] $282 EpiPen [0.3]

25ServierNeuilly-sur-Seine [servier.com]

$4.9 [6.6%] $1,226 Coversil [1.5*]

26ChugaiTokyo, Japan [chugai-pharm.co.jp]

$4.6 [1.3%] $671 Avastin [0.6]

27Mitsubishi TanabeOsaka, Japan [mt-pharma.co.jp]

$4.4 [2.4%] $897 Remicade [0.5]

28 MenariniFlorence, Italy [menarini.com] $4.0* [0.2%] N/A Migard/Allegro [0.1*]

29GenzymeCambridge, Massachusetts [genzyme.com]

$4.0 [2.3%] $847 Cerezyme [0.7]

30AllerganIrvine, Caliornia [allergan.com]

$4.0 [7.9%] $805 Botox [1.4]



8/12

Sponsored by

www.dsm.com

MAY 2011 www.pharmexec.com 51

25 Galen Holdings24 Purdue

23 Nestle S.A.22 Watson

21 Novo Nordisk20 Eisai

19 Otsuka America18 Gilead17 Mylan16 Forest15 Takeda

14 Boehringer Ingelheim13 Bristol-Myers Squibb

12 Sanofi-Aventis11 Abbott10 Amgen

9 Johnson & Johnson8 GlaxoSmithKline

7 Teva6 Roche5 Lilly

4 Novartis

3 AstraZeneca2 Merck1 Pfizer

25 Aurobindo24 Sanofi-Aventis

23 Par22 Bristol-Myers Squibb

21 Ranbaxy20 Forest

19 West Ward18 Lilly

17 Zydus16 Abbot

15 Dr Reddy14 Actavis U.S.

13Boehringer Ingelheim

12 GlaxoSmithKline11 Covidien

10 AstraZeneca9 Amneal8 Merck7 Lupin6 Endo

5 Watson4 Pfizer

3 Novartis2 Mylan1 Teva

25 Singulair24 gabapentin

23 Plavix

22 ibuprofen (Rx)21 oxycodone/acetaminophen

20 warfarin sodium19 citalopram HBR

18 metoprolol succinate17 sertraline HCL

16 atenolol15 zolpidem tartrate

14 metoprolol tartrate13 furosemide

12 Lipitor11 alprazolam

10 hydrochlorothiazide9 metformin HCL

8 amoxicillin7 azithromycin

6 omeprazole (RX)5 amlodipine besylate4 levothyroxine sodium

3 lisinopril2 simvastatin

1 hydrocodone/acetaminophen

Top 25 Corporations by U.S. SalesProduct 2010 2009 % Change

Top 25 Corporations by PrescriptionsCorporation 2010 2009 % Change

Top 25 U.S. Pharma Products by PrescriptionsProduct 2010 2009 % Change

26.2 27.8 -5.75 18.8 19.8 -5.05 18.3 18.3 FLAT

15.7 13.2 18.94 14.3 13.2 8.33 13.8 14.2 -2.82 13.7 12.1 13.22 13.6 15.0 -9.33 12.9 12.8 0.78 12.7 12.5 1.60 10.8 10.6 1.89 10.4 11.2 -7.14 9.7 9.0 7.77 6.4 7.6 -15.79 6.0 7.9 -24.05 4.7 4.4 6.82 4.7 3.9 20.51 4.7 3.9 20.51 4.6 4.0 15.00 4.6 4.4 4.54 4.5 3.7 21.62 3.3 3.2 3.12 3.2 2.8 14.28 3.2 3.0 6.67 3.0 2.8 7.14

639.3 629.8 1.51 379.9 347.2 9.41 265.3 240.9 10.13 242.0 265.7 -8.92 233.6 235.1 -0.64 141.0 114.5 23.14 134.0 96.2 39.29 104.2 123.3 -15.49 97.9 67.5 45.04 86.8 93.8 -7.46 80.2 91.2 -12.06

72.6 78.2 -7.16

71.1 72.4 -1.79 68.1 71.1 -4.22 63.5 73.5 -13.60 58.1 61.0 -4.75 53.9 34.9 54.44 49.5 49.8 -0.60 45.2 34.3 31.78 44.3 46.2 -4.11 42.5 31.0 37.09 42.2 44.1 -4.31 40.2 48.2 -16.60 40.0 42.1 -4.99 39.7 38.9 2.06

131.2 128.2 2.34 94.1 83.8 12.29 87.4 82.8 5.56 70.5 66.0 6.82 57.2 51.3 11.5 53.4 45.4 17.62 52.6 53.8 -2.23 52.3 52.4 -0.19 48.3 44.3 9.03 47.8 47.9 -0.21 46.3 43.9 5.47 45.3 51.7 -12.38 43.4 43.5 -0.23 38.9 41.1 -5.35 38.0 35.1 8.26 36.3 39.3 -7.63 35.7 34.2 4.38 33.0 26.9 22.68 32.1 27.1 18.45 32.0 31.6 1.27 31.9 30.2 5.63 31.1 30.3 2.64

29.5 29.9 -1.34 29.3 25.4 15.35 28.7 28.6 0.35

Figures (rounded) in millions

Source:IMSHealth

Source:IMS

Health

Sourc

e:IMSHealth




Figures (rounded) in billions

Figures (rounded) in millions


9/12

Sponsored by

www.dsm.com


2011Rank

CompanyHQ [website]




31ForestNew York, New York [rx.com]

$3.9 [7.4%] $1,054 Lexapro [2.3]

32CSLVictoria, Australia [csl.com.au]

$3.8 [3.6%] $272 N/A [N/A]

33UCB

Brussels, Belgium [ucb.com]

$3.7 [4.0%] $1,044 Keppra [1.2]

34OtsukaTokyo, Japan [www.otsuka.co.jp/en/]

$3.6* [46.1%] N/A Abiliy [4.5*]

35CelgeneSummit, New Jersey [celgene.com]

$3.5 [36.7%] $1,128 Revlimid [2.5]

36Biogen IdecWeston, Massachusetts [biogenidec.com]

$3.5 [10.1%] $1,249 Avonex [3.5]

37ShireDublin, Ireland [shire.com]

$3.1 [16.1%] $662 Vyvanse [0.6]

38 AlconHnenberg, Switzerland [alcon.com] $3.1 [14.5%] $747Glaucoma products [1.3]

39Warner ChilcottDublin, Ireland [wcrx.com]

$2.9 [111.0%] $147 Actonel [1.0]

40CephalonFrazer, Pennsylvania [cephalon.com]

$2.8 [28.3%] $440 Provigil [1.1]



10/12

Sponsored by

www.dsm.com


20 Calcium Antagonists

19 Hormonal Contraception

18 Antirheumatics (Non-steroid)

17 Multiple Sclerosis

16 Vaccines15 Erythropoietin Products

14 Cephalosporins & Combs


12 Antiepileptics

11 Platelet Aggreg. Inhibitors

10 HIV Antivirals

9 Antidepressants

8 Autoimmune Agents

7 Antipsychotics

6 Angiotensin II Antagonists

5 Antiulcerants

4 Antidiabetics


2 Lipid Regulators

1 Oncologics

20 Diovan (valsartan)19

Herceptin (trastuzumab)

18 Lovenox (enoxaparin sodium)17 Actos (pioglitazone)

16 Aricept (donepezil)15 Lantus (insulin glargine)

14 Mabthera (rituximab)

13 Abilify (aripiprazole)12 Singulair (montelukast)

11 Avastin (bevacizumab)

10 Zyprexa (olanzapine)9 Humira (adalimumab)

8 Remicade (infliximab)7 Enbrel (etanercept)

6 Crestor (rosuvastatin)

5 Seroquel (quetiapine)4 Nexium (esomeprazole)

3 Seretide (fluticasone/salmeterol)

2 Plavix (clopidogrel)1 Lipitor (atorvastatin)

Source:IMSHealth,

MIDAS

Source:IMSH

ealth,

MIDAS

Source:IMSHealth

Top 20 Global Therapy Classes by SalesProduct 2010 % Change

Top US Patent ExpiriesRank Product/Company LOE date 2010 Sales Total Rx 2010

Top 20 Leading Global Products by SalesProduct 2010 % Change

1 LIPITOR/Pzer Q4 2011 7,244.1 45.82 ADVAIR DISKUS/GSK Q3 2011 4,711.4 19.7

3 ZYPREXA/Eli Lilly Q4 2011 2,957.6 5.3

4 LEVAQUIN/Ortho-McNeil Q2 2011 1,522.4 10.9

5 XALATAN/Pzer Q1 2011 710.8 6.9

6 FEMARA/Novartis Q2 2011 681.6 1.3

7 ZYPREXA ZYDIS/Eli Lilly Q4 2011 331.1 0.4

8 ADVAIR HFA/GSK Q3 2011 254.6 1.1

9 PATANOL/Alcon Q2 2011 241.1 2.3

10 PATADAY/Alcon Q2 2011 215.0 2.1

11 VIVELLE-DOT/Novogyne Q1 2011 215.0 3.2

56.0 6.7 36.4 2.0 35.8 7.0 34.4 12.2 27.2 -6.7 26.6 4.5 25.4 9.0 20.7 14.7 20.2 3.4 15.4 13.2 14.6 1.5 12.6 -3.3 12.0 6.4 11.6 5.8

10.6 -1.8 10.5 3.5 9.8 13.9 9.8 3.6 9.5 5.3 9.2 -8.8

12,656.1 -6.2 8,816.5 -3.4 8,468.6 4.4 8,361.5 1.3 6,815.6 13.2 6,796.3 24 6,167.2 5.2 6,038.6 10.3 5,959.5 19.7 5,736.3 6.6 5,532.2 11.1 5,465.4 9.1 5,430.3 16.3 5,033.2 7.8 4,685.3 16.7 4,432.1 8.5 4,317.3 3.9 4,282.0 -5.3

4,165.1 6.7 4,156.4 3.5

Sales gures (rounded) in USD millions; Rx gures rounded LOE = Loss o Exclusivi ty

Figures (rounded) in USD billions (Dec 2009Dec 2010)Sales represent audited market or pharma products only

IMS gures do not account or o-invoice discounts/rebates and can vary rom reported mr sales

Figures (rounded) in USD millions (Dec. 2009Dec. 2010)Sales represent audited market or pharma products only Figures do not account or o-invoice discounts/rebates and can vary rom reported mr sales


TOTAL US SCRIP MARKET: 2010: $123,315.5 2009: 116,221.7 6.10% Increase


11/12

Sponsored by

www.dsm.com


2011Rank

CompanyHQ [website]




41WatsonCorona, Caliornia [watson.com]

$2.6 [27.0%] $296 CNS generics [0.9]

42LundbeckCopenhagen, Denmark [lundbeck.com]

$2.6 [0.6%] $542 Cipralex/Lexapro [1.5]

43Kyowa Hakko KirinTokyo, Japan [kyowa-kirin.co.jp]

$2.6 [14.7%] $429 Nesp/Espo [0.6*]

44Dainippon SumitomoOsaka, Japan [ds-pharma.co.jp]

$2.6 [20.1%] $554 Amlodin [0.6]

45ShionogiOsaka, Japan [shionogi.co.jp]

$2.4* [35.2%] $135 Crestor [0.3]

46ActavisHanarjrur, Iceland [actavis.com]

$2.4* [32.5%] N/A Oxycodone [0.4]

47HospiraLake Forest, Illinois [hospira.com]

$2.3 [13.3%] $301 N/A [N/A]

48NycomedZurich, Switzerland [nycomed.com]

$2.2 [20.2%] $281 Pantoprazole [1.2]

49ApotexNorth York, Ontario, Canada [apotex.com]

$2.1* [19.2%] N/A N/A [N/A]

50StadaBad Vilbel, Germany [stada.de]

$2.1 [5.0%] $73 Generic omeprazole [0.1]


TOTALS: 2010: $593.4 billion 2009: $550.5 billion 7.79%


12/12

Sponsored by


1. PfzerPresident and CEOJe Kindler retired, succeeded by Ian C.

Read. George Lorch elected Non-Execu-

tive Chairman o the Board. Sutent ap-

proved in EU or treatment o pancreatic

neuro-endocrine tumors. Launched

Prevnar 13, a vaccine against 13 strains

o pneumococcal diseases in inants

and young children. Also has 118

products in the R&D pipeline and had

1,300 clinical trials in 2010.

2. Novartis Completed purchaseo Alcon rom Nestl or $38.7 billion.

Jonathan Symonds promoted to CFO.

David Epstein replaced CEO Joe Jimenez

as Division Head, Pharmaceuticals.

Thirteen major pharmaceutical approvals

in the US, Europe, and Japan, with 147

products in development. Tasigna was ap-

proved in the US, the EU, Japan, and Swit-

zerland or patients with newly diagnosed

Philadelphia chromosome-positive chronic

myeloid leukemia (Ph+ CML), a orm oblood cancer. Menveo (vaccine against

meningococcal disease) launched in the

US, EU, and parts o Latin America and

Asia. Sandoz launched generic enoxaparin,

its most successul launch to date, and

acquired Oriel Therapeutics.

3. Sanof-Aventis Initiatedacquisition o Genzyme or $16.6 billion

(completed in April) and nished

acquisition o OTC company Chattem.

Began collaboration programs with

Harvard and Columbia Universities

and a research alliance with Scripps

Genomic Medicine. Jevtana approved

in US or second-line treatment o

metastatic hormone-reractory

prostate cancer.

4. MerckElected Kenneth Frazier CEO.Bought Inspire or $430 million. Rotateq

vaccine awarded top honor at Prix Galien

USA 2010. Merck BioVentures entered into

an alliance with Parexel or biosimilar devel-

opment. Signed commercialization agree-

ment with Lundbeck or Sycrest and a letter

o mutual intent with Chinas Sinopharm.

Pipeline has more than 20 late-stage can-

didates. Licensed oral mTOR inhibitor or

multiple cancers rom Ariad. Oral hepatitis

C protease inhibitor Boceprevir grantedPriority Review status by FDA.

5. Roche Rituxan approved in US asrst-line treatment or chronic lymphocytic

leukemia (CLL) and relapsed/reractory

CLL. Tarceva approved in US and EU

or rst-line treatment o non-small-cell

lung cancer ater chemotherapy. FDA

rejected use o Avastin as a treatment

or metastatic breast cancer; Roche

has requested a hearing to appeal this

decision. Daniel ODay appointed COO othe Pharmaceuticals division. Alan Hippe

named CFO. Jean-Jacques Garaud

appointed Head o Roche Pharma

Research and Early Development.

6. GlaxoSmithKline Benlysta(belimumab, the rst new lupus treatment

in 60 years) approved by FDA in March. Six

products in total approved by US and EU;

seven more led with regulators. Malaria

vaccine in Phase III trials in Arica, with

30 other late-stage assets. Julian Heslop

retired as CFO, succeeded by Simon

Dingemans. Patents or active ingredients

in Seretide/Advair expired.

7. AstraZeneca Crestor substancepatent upheld in US court. Approvals

include Vimovo (naproxen/esomeprazole

magnesium) in US and EU and Brilique

(atherothrombotic event prevention) in

EU. Kombiglyze XR, the only once-daily

dose o DPP4/metormin, developed with

Bristol-Myers Squibb, also approved in

US. Nine molecules in Phase III trials or

submitted or regulatory approval, with

another 92 projects in development. Com-

pleted deal with Rigel or development o

ostamatinib (rheumatoid arthritis).

8. Johnson & JohnsonCompleted

tender oer or Crucell N.V. in February2011; acquired 98.93 percent o shares.

Products under regulatory review include:

Rivaroxoban or stroke prevention in pa-

tients with atrial brillation (US), Telaprevir

or hepatitis C (US and EU), Abiraterone

acetate or metastatic advanced prostate

(US and EU), and rilpivirine or HIV. Eight

more candidates planned or regulatory

submission rom 2011 to 2013.

9. Eli LillyCompleted acquisition oAlnara and Avid Radiopharmaceuticals.Launched statin Livalo in the US with part-

ner Kowa. Has 68 molecules in develop-

ment. Several monoclonal antibodies or

cancer in late-stage development. Phase

III candidates include Necitumumab

or non-small-cell lung cancer and Ramu-

cirumab or metastatic breast and gastric

cancers. Signed commercialization deal

with Acrux or newly approved experimen-

tal testosterone solution Axiron.

10. AbbottThe year was marked byacquisitions, including the pharmaceuti-

cal business o Solvay or $6.1 billion

plus milestones, and Piramal Healthcares

Healthcare Solutions business, a leader

in the Indian branded generics market, or

$2.2 billion in cash, plus $1.6 billion in

annual payments through 2014. Additional

acquisitions included Advanced Medical Op-

tics, STARLIMS Technologies (inormatics),

and the remaining shares o Facet Biotech.

The Top 10 Year In Review

Jerry Cacciotti is a Partner in Oliver Wymans Health and Lie Sciences

Practice. He can be reached at [email protected]

Patrick Clinton is Marketing Director in the Health & Lie Sciences practice

o Oliver Wyman. He can be reached at [email protected]

About the Authors

top pharama companies 2011 rpt

Documents